News | Atrial Fibrillation | May 13, 2020

Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation

PRECEPT Trial shows 15-month freedom from persistent atrial fibrillation in 80.4 percent of patients who underwent cardiac ablation using the Thermocool Smarttouch SF Catheter

Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020

May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the treatment of persistent atrial fibrillation (AF), resulted in freedom from any documented, symptomatic atrial arrhythmias at 15 months post-procedure for eight out of ten study participants (80.4 percent).[1] The trial was presented as a late-breaking study at the Heart Rhythm Society (HRS) 2020 Science virtual meeting. Data from the PRECEPT study was also recently published in JACC: Clinical Electrophysiology.[1]

This PRECEPT study data will be used to support a premarket approval (PMA) supplement application to the U.S. Food and Drug Administration. 

Atrial fibrillation (AF) is a significant public health issue affecting millions of people and placing a critical burden on healthcare systems. In the U.S., there are 5.5 million patients diagnosed with AF, and it's estimated to grow to more than 7 million by 2035.[2]

"Catheter ablation therapy is a widely accepted treatment option for atrial fibrillation, and the success in paroxysmal atrial fibrillation has been well established," said Moussa Mansour, M.D., associate professor in medicine at Harvard Medical School, director of both the cardiac electrophysiology laboratory and the atrial fibrillation programat Massachusetts General Hospital, and study investigator. "This data is encouraging and demonstrates that patient-tailored, radiofrequency catheter ablation therapy may provide a clinically meaningful benefit to patients with persistent atrial fibrillation, who are at an even higher risk for stroke and other complications."

Persistent AF is defined as continuous AF that lasts for more than seven days, while paroxysmal AF stops on its own or with intervention within seven days.[3] Approximately one-third of patients with paroxysmal AF will progress to persistent AF with 15 percent progressing within one year.[4,5] There is an increased physical and economic burden resulting from persistent AF, and it is associated with a higher risk of stroke, heart failure, and mortality.[6]  The management of persistent AF aims to prevent AF recurrence and associated disabilities while reducing side effects from treatment.

The PRECEPT study is the first prospective, multicenter investigational device exemption study designed to evaluate the safety and effectiveness of radiofrequency catheter ablation in patients with persistent AF, and was conducted using the Thermocool Smarttouch SF Catheter. The primary effectiveness endpoint was freedom from documented recurrence of atrial flutter/atrial tachycardia episodes of 30 seconds or longer and freedom from additional five failure modes: acute procedural failure, use of non-study catheter, repeat procedures, use of new/higher dose antiarrhythmic drugs, surgical AF ablation. At 15 months post-procedure, 86.1 percent of patients had freedom from the need for repeat ablation, and 80.4 percent of patients remained free from any documented, symptomatic atrial arrythmias.[1]

About the PRECEPT Study

The PRECEPT study utilized the VISTAG Module included in the CARTO 3 System and Thermocool Smarttouch SF Catheter to conduct patient-specific tailored ablation strategies requiring the isolation of all pulmonary veins and allowed for additional left atrium ablations when needed. A total of 381 patients with drug-refractory symptomatic persistent AF were enrolled at 27 centers in the U.S. and Canada. All patients received pulmonary vein isolation of all veins, and 44.5 percent of patients also received additional left atrium ablations. Primary adverse events occurred in 3.8 percent of patients, a rate similar to those reported in paroxysmal atrial fibrillation studies.[7,8] The average procedure time was under three hours (178 minutes), with an average fluoroscopy time of 15.3 minutes.[1]

What is Atrial Fibrillation

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia (abnormal heart rhythm) and affects nearly one percent of the population.[9] During AF, the upper chambers of the heart, the atria, beat rapidly or in an uncontrolled manner, which can feel like a flutter. When the heart beats erratically, it does not pump blood as efficiently as it should. When oxygen is not being properly delivered to all parts of the body, the patient may feel ill or experience other AF symptoms. Atrial fibrillation may not be life-threatening; however, it is important to seek treatment to control the symptoms, as AF can lead to stroke.

For more information: www.biosensewebster.com

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

References:

1. Moussa Mansour, Hugh Calkins, Jose Osorio, et al. Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT Trial. JACC: Clinical Electrophysiology. May 2020. DOI: 10.1016/j.jacep.2020.04.024.

2. Khavjou, Olga, D. Phelps, and A. Leib. Projections of cardiovascular disease prevalence and costs: 2015–2035. November 2016. Dallas: American Heart Association (2016).

3. Hugh Calkins, Gerhard Hindricks, Ricardo Cappato, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter ablation and surgical ablation of atrial fibrillation. 2017.

4. Pillarisetti J, Patel A, Boc K, et al. Evolution of Paroxysmal Atrial Fibrillation to Persistent or Permanent Atrial Fibrillation: Predictors of Progression. J Atr Fibrillation. 2009;2(1):191. Published 2009 Jun 1. doi:10.4022/jafib.191.

5. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG et al. (2010) Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 55 (8): 725-731.

6. Chen LY, Chung MK, Allen LA, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e623-e644.

7. Natale A, Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol. 2014;64(7):647-656.

8. Chinitz LA, Melby DP, Marchlinski FE, et al. Safety and efficiency of porous-tip contact-force catheter for drug-refractory symptomatic paroxysmal atrial fibrillation ablation: results from the SMART SF trial. Europace. 2018;20(FI_3):f392-f400.

9. Johan E.P. Waktare, MB, ChB, MRCP, Atrial Fibrillation, AHA Journals.org.
 

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve